Anne Mounsey, MD Anthony J. Viera, MD, MPH Rosalie Dominik, DrPH Department of Family Medicine, University of North Carolina at Chapel Hill (Drs. Mounsey and Viera); Department of Biostatics, Gillings School of Global Public Health (Dr. Dominik) anne_mounsey@med.unc.edu
The authors reported no potential conflict of interest relevant to this article. This work was supported by a grant from the National Research Center for Research Resources.
To continue with our example, the RE-LY trial was well conducted. Randomization was performed centrally via an automated telephone system and 2 doses of dabigatran were administered in a masked fashion, while warfarin was open-label. Remarkably, follow-up was achieved for 99.9% of participants over a median of 2 years, and independent adjudicators masked to treatment group assessed outcomes.4,5
CORRESPONDENCE Anne Mounsey, MD, UNC Chapel Hill Department of Family Medicine, 590 Manning Drive, CB 7595, Chapel Hill, NC 27590; anne_mounsey@med.unc.edu
